HRP20140066T1 - Derivati kvinazolina - Google Patents
Derivati kvinazolina Download PDFInfo
- Publication number
- HRP20140066T1 HRP20140066T1 HRP20140066AT HRP20140066T HRP20140066T1 HR P20140066 T1 HRP20140066 T1 HR P20140066T1 HR P20140066A T HRP20140066A T HR P20140066AT HR P20140066 T HRP20140066 T HR P20140066T HR P20140066 T1 HRP20140066 T1 HR P20140066T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- alkyl
- alkynyl
- Prior art date
Links
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000000304 alkynyl group Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000003342 alkenyl group Chemical group 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- -1 nitro, amino Chemical group 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Claims (15)
1. Spoj slijedeće formule:
[image]
i/ili njegova farmaceutski prihvatljiva sol gdje
svaki od R1, R2, i R3 nezavisno, je H, halo, nitro, amino, cijano, hidroksi, alkil, alkenil, alkinil, aril, cikloalkil, heterocikloalkil, heteroaril, alkoksi, alkiltio, alkilkarbonil, karboksi, alkoksikarbonil, karbonilamino, sulfonilamino, aminokarbonil, ili aminosulfonil;
jedan od R3 i R4 je
[image]
gdje n je 1, 2, 3, 4, ili 5; svaki od Ra, Rb, i Rc, nezavisno, je H, alkil, alkenil, alkinil, cikloalkil, heterocikloalkil, aril, ili heteroalil, ili Rb i Rc, zajedno sa atomom dušika na koji su prikvačeni, čine zasićeni, nezasićeni ili aromatski prsten sa 3-12 članova koji sadrži 1-3 heteroatoma izabrana iz N, O i S; te svaki od Rd i Rc, nezavisno, je H, alkil, alkenil, ili alkinil; ili Rd i Rc, zajedno sa atomom dušika na koji su prikvačeni, čine zasićeni, nezasićeni ili aromatski prsten sa 3-12 članova koji sadrži 1-3 heteroatoma izabrana iz N, O i S; te je drugi od R3 i R4 H, halo, nitro, amino, cijano, hidroksi, alkil, alkenil, alkinil, aril, cikloalkil, heterocikloalkil, heteroaril, alkoksi, alkiltio, alkilkarbonil, karboksi, alkoksikarbonil, karbonilamino, sulfonilamino, aminokarbonil, ili aminosulfonil;
X je O, S ili NRf, pri čemu je Rf H, alkil, alkenil, alkinil, aril, cikloalkil, heterocikloalkil, heteroaril, alkilkarbonil, alkoksikarbonil, aminokarbonil, ili aminosulfonil;
Y je fenil supstituiran sa alkinilom, ili spojen sa drugim prstenom od 3-8 članova; te
Z je N ili C-CN.
2. Spoj patentnog zahtjeva 1 i/ili njegova farmaceutski prihvatljiva sol, naznačen time da Z je N.
3. Spoj patentnog zahtjeva 1 i/ili njegova farmaceutski prihvatljiva sol, naznačen time da X je O, NH, ili N-CH3
4. Spoj patentnog zahtjeva 1 i/ili njegova farmaceutski prihvatljiva sol, naznačen time da Y je
[image]
5. Spoj patentnog zahtjeva 4 i/ili njegova farmaceutski prihvatljiva sol, naznačen time da X je O, NH, ili N-CH3 te i je N.
6. Spoj patentnog zahtjeva 1 ili 5 i/ili njegova farmaceutski prihvatljiva sol, naznačen time da je jedno od R3 i R4
[image]
gdje n je 1 i svaki od Ra, Rb, i Rc, nezavisno, je H, alkil, alkenil, alkinil, cikloalkil, heterocikloalkil, aril, ili heteroaril.
7. Spoj patentnog zahtjeva 1 ili 5 i/ili njegova farmaceutski prihvatljiva sol, naznačen time da je jedno od R3 i R4
[image]
gdje n je 1 ili 2; Ra je H, alkil, alkenil, alkinil, cikloalkil, heterocikloalkil, aril, ili heteroaril; te Rb i Rc, zajedno sa atomom dušika na koji su prikvačeni, čine zasićeni, nezasićeni ili aromatski prsten sa 3-12 članova koji sadrži 1-3 heteroatoma izabrana iz N, O i S.
8. Spoj patentnog zahtjeva 7 i/ili njegova farmaceutski prihvatljiva sol, naznačen time da Rb i Rc, zajedno sa atomom dušika na koji su prikvačeni, čine biciklički prsten slijedeće formule:
[image]
gdje svaki od m1, m2, m3 i m4, nezavisno, je 0, 1, 2, ili 3; A je N ili CR; B je NR ili CRR', svaki R i R', nezavisno, je H, alkil, ili halo; te svaki od Ri, Rii, Riii, Riv, Rv, Rvi, Rvii i Rviii, nezavisno, je H, alkil, ili halo.
9. Spoj patentnog zahtjeva 1 ili 5 i/ili njegova farmaceutski prihvatljiva sol, naznačen time da je jedno od R3 i R4
[image]
gdje Ra je H, alkil, alkenil, alkinil, cikloalkil, heterocikloalkil, aril, ili heteroaril.
10. Spoj patentnog zahtjeva 1 ili 5 i/ili njegova farmaceutski prihvatljiva sol, naznačen time da je jedno od R3 i R4
[image]
gdje Ra je H, alkil, alkenil, alkinil, cikloalkil, heterocikloalkil, aril, ili heteroaril; te svaki od Rd i Re, nezavisno, je H, alkil, alkenil, ili alkinil.
11. Spoj patentnog zahtjeva 1 ili 5 i/ili njegova farmaceutski prihvatljiva sol, naznačen time da je jedno od R3 i R4
[image]
gdje Ra je H, alkil, alkenil, ili alkinil; te Rd i Re zajedno sa atomom dušika na koji su prikvačeni, čine zasićeni, nezasićeni ili aromatski prsten sa 3-12 članova koji sadrži 1-3 heteroatoma izabrana iz N, O i S.
12. Spoj patentnog zahtjeva 1 i/ili njegova farmaceutski prihvatljiva sol, naznačen time da je spoj bilo koji od spojeva 1-80, 84-91, 93-101, 103, 104 i 106-170.
13. Farmaceutski pripravak, koji sadrži spoj patentnog zahtjeva 1 i/ili njegovu farmaceutski prihvatljivu sol te farmaceutski prihvatljivi nosač istog.
14. Spoj patentnog zahtjeva 1 i/ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju raka.
15. Spoj za uporabu prema patentnom zahtjevu 14 i/ili njegova farmaceutski prihvatljiva sol, naznačen time da je rak rak pluća, rak glave ili vrata, kolorektalni rak, ili rak gušterače.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/164,610 US8426430B2 (en) | 2008-06-30 | 2008-06-30 | Quinazoline derivatives |
| PCT/US2009/049182 WO2010002845A2 (en) | 2008-06-30 | 2009-06-30 | Quinazoline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20140066T1 true HRP20140066T1 (hr) | 2014-02-28 |
| HRP20140066T8 HRP20140066T8 (en) | 2014-03-28 |
Family
ID=41466556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140066AT HRP20140066T8 (en) | 2008-06-30 | 2014-01-21 | Quinazoline derivatives |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8426430B2 (hr) |
| EP (1) | EP2318378B1 (hr) |
| JP (1) | JP5602729B2 (hr) |
| KR (1) | KR101664503B1 (hr) |
| AU (1) | AU2009267136B2 (hr) |
| BR (1) | BRPI0908635B8 (hr) |
| CA (1) | CA2726040C (hr) |
| CY (1) | CY1114842T1 (hr) |
| DK (1) | DK2318378T3 (hr) |
| ES (1) | ES2442946T3 (hr) |
| HR (1) | HRP20140066T8 (hr) |
| MX (1) | MX2010012692A (hr) |
| MY (1) | MY150493A (hr) |
| NZ (1) | NZ589191A (hr) |
| PH (1) | PH12010502934A1 (hr) |
| PL (1) | PL2318378T3 (hr) |
| PT (1) | PT2318378E (hr) |
| RU (1) | RU2505534C2 (hr) |
| SG (2) | SG10201604677RA (hr) |
| SI (1) | SI2318378T1 (hr) |
| TW (1) | TWI407962B (hr) |
| WO (1) | WO2010002845A2 (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9166071B2 (en) | 2009-10-27 | 2015-10-20 | Silicor Materials Inc. | Polarization resistant solar cell design using an oxygen-rich interface layer |
| CN102311438A (zh) * | 2010-06-30 | 2012-01-11 | 和记黄埔医药（上海）有限公司 | 喹唑啉化合物 |
| CN102906086B (zh) * | 2010-06-30 | 2014-02-12 | 和记黄埔医药（上海）有限公司 | 喹唑啉化合物 |
| WO2012000182A1 (en) * | 2010-06-30 | 2012-01-05 | Hutchison Medipharma Limited | Quinazoline compounds |
| TWI466888B (zh) * | 2011-05-25 | 2015-01-01 | Hutchison Medipharma Ltd | 喹唑啉化合物 |
| TWI577671B (zh) * | 2011-11-14 | 2017-04-11 | Sunshine Lake Pharma Co Ltd | Aminoquinazoline derivatives and salts thereof and methods of use thereof |
| CN102659692B (zh) | 2012-05-04 | 2014-04-09 | 郑州泰基鸿诺药物科技有限公司 | 双联厄洛替尼及其制备方法 |
| CN102702115A (zh) * | 2012-05-24 | 2012-10-03 | 盛世泰科生物医药技术(苏州)有限公司 | 一种4-氯-7-氟-6-硝基喹唑啉的合成方法 |
| CN102775315A (zh) * | 2012-07-31 | 2012-11-14 | 上海应用技术学院 | 一种间氨基苯乙炔的制备方法 |
| CN103275018B (zh) * | 2013-04-26 | 2016-03-02 | 浙江工业大学 | 4-[3-氯-4-取代苯胺基]-6-取代甲酰氨基喹唑啉类化合物及制备和应用 |
| CN108863951A (zh) * | 2017-05-16 | 2018-11-23 | 和记黄埔医药（上海）有限公司 | 化合物的盐及其晶型 |
| WO2020007219A1 (zh) * | 2018-07-02 | 2020-01-09 | 南京明德新药研发有限公司 | 一种egfr抑制剂的晶型及其制备方法 |
| CN110903253B (zh) * | 2019-12-13 | 2020-12-25 | 西安交通大学医学院第一附属医院 | 一种喹唑啉酮类化合物及其制备方法和应用 |
| WO2023030216A1 (zh) * | 2021-08-30 | 2023-03-09 | 浙江海正药业股份有限公司 | 喹唑啉类衍生物、或其制备方法和用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| US5430148A (en) * | 1992-03-31 | 1995-07-04 | Agouron Pharmaceuticals, Inc. | Antiproliferative quinazolines |
| JP2994165B2 (ja) * | 1992-06-26 | 1999-12-27 | ゼネカ・リミテッド | キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤 |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| PL190489B1 (pl) * | 1996-04-12 | 2005-12-30 | Warner Lambert Co | Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US6235741B1 (en) | 1997-05-30 | 2001-05-22 | Merck & Co., Inc. | Angiogenesis inhibitors |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| HUP0004286A3 (en) | 1997-11-06 | 2002-01-28 | American Cyanamid Co Madison | Use of quinazoline derivatives for producing pharmaceutical compositions for treating colonic polyps |
| HU230000B1 (en) | 1999-02-10 | 2015-04-28 | Astrazeneca Ab | Intermediates for the preparation of angiogenesis inhibitory quinazoline derivatives |
| US6943161B2 (en) | 1999-12-28 | 2005-09-13 | Pharmacopela Drug Discovery, Inc. | Pyrimidine and triazine kinase inhibitors |
| AU2001264159A1 (en) | 2000-06-22 | 2002-01-02 | Pfizer Products Inc. | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| DE10063435A1 (de) | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| CA2439143A1 (en) * | 2001-02-26 | 2002-09-06 | Mcgill University | Combi-molecules having signal transduction inhibitory properties and dna damaging properties |
| WO2002070477A1 (fr) | 2001-03-01 | 2002-09-12 | Ono Pharmaceutical Co., Ltd. | Acide 2-methylindole-4-acetique, son procede de production et procede pour produire un produit intermediaire de celui-ci |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| DE10204462A1 (de) | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| IL166241A0 (en) | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
| PA8603801A1 (es) | 2003-05-27 | 2004-12-16 | Janssen Pharmaceutica Nv | Derivados de la quinazolina |
| US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| GB0321710D0 (en) | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
| NZ547009A (en) | 2003-12-23 | 2009-09-25 | Pfizer | Novel quinoline derivatives |
| WO2006071079A1 (en) | 2004-12-29 | 2006-07-06 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof |
| KR100735639B1 (ko) * | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
| EP1890703B1 (en) | 2005-06-14 | 2016-05-11 | Taigen Biotechnology | Pyrimidine compounds as chemokine receptors inhibitors |
| WO2007063934A1 (ja) * | 2005-12-02 | 2007-06-07 | Mitsubishi Tanabe Pharma Corporation | 脂環式複素環化合物 |
| US8877764B2 (en) | 2006-09-18 | 2014-11-04 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring EGFR mutations |
-
2008
- 2008-06-30 US US12/164,610 patent/US8426430B2/en active Active
- 2008-07-04 TW TW097125257A patent/TWI407962B/zh not_active IP Right Cessation
-
2009
- 2009-06-30 EP EP09774296.9A patent/EP2318378B1/en active Active
- 2009-06-30 NZ NZ589191A patent/NZ589191A/xx not_active IP Right Cessation
- 2009-06-30 MY MYPI20105323 patent/MY150493A/en unknown
- 2009-06-30 KR KR1020107025451A patent/KR101664503B1/ko active IP Right Grant
- 2009-06-30 PH PH12010502934A patent/PH12010502934A1/en unknown
- 2009-06-30 CA CA2726040A patent/CA2726040C/en not_active Expired - Fee Related
- 2009-06-30 DK DK09774296.9T patent/DK2318378T3/da active
- 2009-06-30 MX MX2010012692A patent/MX2010012692A/es active IP Right Grant
- 2009-06-30 BR BRPI0908635A patent/BRPI0908635B8/pt not_active IP Right Cessation
- 2009-06-30 WO PCT/US2009/049182 patent/WO2010002845A2/en active Application Filing
- 2009-06-30 SG SG10201604677RA patent/SG10201604677RA/en unknown
- 2009-06-30 PT PT97742969T patent/PT2318378E/pt unknown
- 2009-06-30 SG SG201009559A patent/SG167561A1/en unknown
- 2009-06-30 ES ES09774296.9T patent/ES2442946T3/es active Active
- 2009-06-30 RU RU2011103207/04A patent/RU2505534C2/ru active
- 2009-06-30 PL PL09774296T patent/PL2318378T3/pl unknown
- 2009-06-30 JP JP2011516797A patent/JP5602729B2/ja not_active Expired - Fee Related
- 2009-06-30 SI SI200930832T patent/SI2318378T1/sl unknown
- 2009-06-30 AU AU2009267136A patent/AU2009267136B2/en not_active Ceased
-
2013
- 2013-03-18 US US13/846,140 patent/US20130217661A1/en not_active Abandoned
- 2013-11-26 CY CY20131101057T patent/CY1114842T1/el unknown
-
2014
- 2014-01-21 HR HRP20140066AT patent/HRP20140066T8/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140066T1 (hr) | Derivati kvinazolina | |
| HRP20150954T1 (hr) | Derivati dialkoksikinazolina kao inhibitori kdr | |
| HRP20100477T1 (hr) | Kemijski spojevi | |
| HRP20141169T1 (hr) | Makrocikliäśki inhibitori serin proteaze hepatitisa c | |
| HRP20211218T1 (hr) | Inhibitori receptora fibroblastnog faktora rasta | |
| HRP20210895T1 (hr) | Inhibitori hpk1 i metode za njihovo korištenje | |
| AR063643A1 (es) | Compuestos quimicos derivados de quinolina, un metodo de preparacion y composiciones farmaceuticas | |
| HRP20180483T1 (hr) | Spoj kinolona | |
| HRP20180335T1 (hr) | Kondenzirani derivati imidazola korisni kao ido inhibitori | |
| JP2011526913A5 (ja) | キナゾリン化合物及び同化合物を含む治療薬 | |
| SI2824100T1 (en) | 1,2,5-oxadiazoles as inhibitors of indolamine 2,3-dioxygenase | |
| AR054183A1 (es) | Derivados de piridincarboxamida y su uso como agentes anticancerigenos. procesos de obtencion y composiciones farmaceuticas. | |
| AR094312A1 (es) | Inhibidores del receptor del factor de crecimiento de fibroblastos | |
| AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
| AR056206A1 (es) | Pirazolpirimidinas como inhibidores de protein quinasas | |
| HRP20160077T1 (hr) | Imidazotriazini i imidazopiramidini kao inhibitori kinaze | |
| AR061793A1 (es) | Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica | |
| HRP20140884T1 (hr) | Derivati fenoksipiridinilamida i njihova primjena u lijeäśenju bolesnih stanja posredovanih inhibitorima pde4 | |
| AR049662A1 (es) | Derivados de 1,3-fenilendiamina con efecto inhibitorio de b-raf; un metodo para su preparacion, composiciones farmaceuticas que los contienen y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer | |
| AR054184A1 (es) | Derivados de 1,5 difenilpirazol. procesos de obtencion y composiciones farmaceuticas. | |
| AR050940A1 (es) | Serinamidas sustituidas por heterociclos; procesos para su preparacion; intermediarios para su sintesis; uso de las mismas en la fabricacion de productos fitosanitarios; productos y sus metodos de preparacion y procedimientos para controlar el crecimiento de plantas indeseadas. | |
| PE20140863A1 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
| AR057979A1 (es) | PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS. | |
| AR050545A1 (es) | Derivados de quinazolinonas y su uso como inhibidores de b-raf | |
| AR074052A1 (es) | Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa |